TY  - JOUR
AU  - Wang, Xiao
AU  - Freiesleben, Silka Dawn
AU  - Schneider, Luisa-Sophie
AU  - Preis, Lukas
AU  - Priller, Josef
AU  - Spruth, Eike Jakob
AU  - Altenstein, Slawek
AU  - Schneider, Anja
AU  - Fließbach, Klaus
AU  - Wiltfang, Jens
AU  - Hansen, Niels
AU  - Jessen, Frank
AU  - Rostamzadeh, Ayda
AU  - Duzel, Emrah
AU  - Glanz, Wenzel
AU  - Incesoy, Enise I
AU  - Bürger, Katharina
AU  - Janowitz, Daniel
AU  - Ewers, Michael
AU  - Perneczky, Robert
AU  - Rauchmann, Boris Stephan
AU  - Teipel, Stefan J
AU  - Kilimann, Ingo
AU  - Goerss, Doreen
AU  - Laske, Christoph
AU  - Munk, Matthias H J
AU  - Spottke, Annika
AU  - Roy, Nina
AU  - Heneka, Michael
AU  - Brosseron, Frederic
AU  - Wagner, Michael
AU  - Wolfsgruber, Steffen
AU  - Ramirez, Alfredo
AU  - Kleineidam, Luca
AU  - Stark, Melina
AU  - Peters, Oliver
TI  - Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
JO  - Neurology
VL  - 103
IS  - 8
SN  - 0028-3878
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Ovid
M1  - DZNE-2024-01159
SP  - e209806
PY  - 2024
AB  - CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after the initial manifestation of cognitive symptoms. Thus, further identification of biomarkers is required to detect related pathology in the preclinical stage and predict cognitive decline. Our study aimed to assess the association of neurogranin and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with cognitive decline in individuals with subjective cognitive decline (SCD).We enrolled participants with available neurogranin and BACE1 measurements in CSF from the DELCODE (DZNE-Longitudinal Cognitive Impairment and Dementia, Germany) cohort. The longitudinal change of Preclinical Alzheimer's Cognitive Composite score was assessed as the primary outcome in participants with SCD and controls. The secondary outcome was defined as conversion of SCD to mild cognitive impairment (MCI) during follow-up. Levels of neurogranin, BACE1, and neurogranin/BACE1 ratio across groups were compared by analysis of covariance after adjustment for demographics. The linear mixed-effects model and Cox regression analysis were applied to evaluate their association with cognitive decline and progression of SCD to MCI, respectively.A total of 530 participants (mean age: 70.76 ± 6.01 years, 48.7
KW  - Humans
KW  - Aspartic Acid Endopeptidases: cerebrospinal fluid
KW  - Amyloid Precursor Protein Secretases: cerebrospinal fluid
KW  - Female
KW  - Male
KW  - Cognitive Dysfunction: cerebrospinal fluid
KW  - Aged
KW  - Neurogranin: cerebrospinal fluid
KW  - Disease Progression
KW  - Biomarkers: cerebrospinal fluid
KW  - Longitudinal Studies
KW  - Middle Aged
KW  - Aged, 80 and over
KW  - Aspartic Acid Endopeptidases (NLM Chemicals)
KW  - Amyloid Precursor Protein Secretases (NLM Chemicals)
KW  - Neurogranin (NLM Chemicals)
KW  - BACE1 protein, human (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39303184
DO  - DOI:10.1212/WNL.0000000000209806
UR  - https://pub.dzne.de/record/272342
ER  -